Elicera Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Elicera Therapeutics' es Jamal El-Mosleh, nombrado en Jan 2020, tiene una permanencia de 4.25 años. posee directamente un 7.69% de las acciones de la empresa, con un valor de SEK3.23M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 4.3 años, respectivamente.

Información clave

Jamal El-Mosleh

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.3yrs
Participación del CEO	7.8%
Permanencia media de la dirección	3.8yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Jamal El-Mosleh (42 yo)

4.3yrs

Permanencia

Mr. Jamal El-Mosleh, M.Sc., is Co-Founder at Elicera Therapeutics AB (publ) and has been its CEO since 2020. He was a Director of Elypta AB since 2016 until September 2020. Mr. El-Mosleh served as Chief Ex...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jamal El-Mosleh	CEO & Co-Founder	4.3yrs	sin datos	7.84% SEK 2.6m
Magnus Essand	Chief Science Officer	4.3yrs	sin datos	9.44% SEK 3.1m
Di Yu	Co-Founder & Head of Transitional Research	no data	sin datos	9.44% SEK 3.1m
Ingvar Karlsson	Chief Financial Officer	3.3yrs	sin datos	0.10% SEK 33.8k
Anna Gultekin	Head of Regulatory Affairs	1.3yrs	sin datos	sin datos

3.8yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ELIC se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Magnus Essand	Chief Science Officer	10.3yrs	sin datos	9.44% SEK 3.1m
Margareth Jorvid	Independent Director	4.3yrs	sin datos	0.20% SEK 64.5k
Agneta Edberg	Independent Chairman	4.3yrs	sin datos	0.34% SEK 113.1k
Christina Herder	Independent Director	4.3yrs	sin datos	0.16% SEK 53.1k
Jan Zetterberg	Independent Director	4.3yrs	sin datos	0.20% SEK 67.2k

4.3yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de ELIC se considera experimentada (4.3 años de antigüedad promedio).

Elicera Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

New major risk - Shareholder dilution

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

New major risk - Financial position

Elicera Therapeutics AB (publ) to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1

Elicera Therapeutics AB (Publ) Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301

Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research

Elicera Therapeutics AB (publ) Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application

New major risk - Share price stability

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

Elicera Therapeutics AB (publ) Receives Notice of Allowance for European Patent Protecting the iTANK

New major risk - Financial position

Elicera Therapeutics AB (publ) Submits Clinical Trial Application to Evaluate Its CAR T-Cell Therapy in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Continues Phase I/IIa Study with Oncolytic Virus as Planned, Following Safety Review in Cohort 3

Elicera Therapeutics AB (publ) Announces Positive Clinical Effect in Cancer Trial

Elicera Therapeutics Reports Additional Signals of Clinical Activity in Patients Treated for Neuroendocrine Tumors in the Elc-100 Study At the Oncolytic Virotherapy Summit in Boston

Elicera Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Receives EUR 2.5 Million Funding to Fully Finance Clinical Phase I/II-Trial with its Car T-Cell Therapy, ELC-301

Elicera Therapeutics Successfully Concludes Preclinical Proof-Of-Concept Studies for Oncolytic Virus ELC-201 Confirming the Proposed Mode-Of-Action

High number of new and inexperienced directors

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Enters into Agreement with Baylor College of Medicine for Contract Manufacturing of Next Generation Oncolytic Virus, ELC-201

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad